BeritK
Following discussions with drugmakers, including Sanofi (NASDAQ:SNY) and AstraZeneca (NASDAQ:AZN), the Biden Administration announced Thursday that an additional 230K doses of RSV immunizations will be made available for infants in January. Last month, Sanofi (SNY) and AstraZeneca (AZN) delivered 77K additional doses of Beyfortus. The monoclonal antibody is indicated for the prevention of lung disease caused by Respiratory Syncytial Virus (RSV) in children up to 24 months of age. The latest agreement boosts the supplies further as the U.S. enters the annual respiratory viral season. RSV, a leading cause of respiratory infections across all age groups, can cause lower respiratory tract disease in some infants. According to the American Academy of Pediatrics, each year, RSV leads to hospitalizations in about 1% to 3% of children below the age of 12 months in the U.S.